Dennis R. Benjamin

发表

SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

A. Nesterova, D. Benjamin, Leia M. Smith, 2014, Molecular Cancer Therapeutics.

Metabolites of PPI-2458, a Selective, Irreversible Inhibitor of Methionine Aminopeptidase-2: Structure Determination and In Vivo Activity

C. D. Thompson, C. Arico-Muendel, D. Benjamin, 2013, Drug Metabolism and Disposition.

DMD048355 814..826

C. D. Thompson, C. Arico-Muendel, D. Benjamin, 2013 .

Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates.

D. Benjamin, S. Hengel, S. Alley, 2016, Bioanalysis.

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

D. Benjamin, P. Senter, S. Alley, 2010, Clinical Cancer Research.

Antibody‐Drug Conjugate Therapy

S. Alley, C. Law, Dennis R. Benjamin, 2009 .

The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity

D. Benjamin, P. Senter, S. Alley, 2009, Journal of Pharmacology and Experimental Therapeutics.

Contribution of linker stability to the activities of anticancer immunoconjugates.

Damon L. Meyer, D. Benjamin, P. Senter, 2008, Bioconjugate chemistry.

Orally active fumagillin analogues: transformations of a reactive warhead in the gastric environment.

C. D. Thompson, Amy A Sarjeant, C. Arico-Muendel, 2013, ACS medicinal chemistry letters.

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

I. Bernstein, P. Burke, R. Walter, 2013, Blood.

Development of orally active inhibitors of protein and cellular fucosylation

P. Burke, D. Benjamin, P. Senter, 2013, Proceedings of the National Academy of Sciences.

Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates

D. Benjamin, M. Jonas, C. Law, 2017, Molecular Cancer Therapeutics.

Abstract 4393: ASG-5ME is a novel antibody drug conjugate (ADC) for treating prostate cancers

A. Raitano, Z. An, Leia M. Smith, 2010 .

Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.

Kim K. Emmerton, D. Benjamin, N. Okeley, 2016, Cancer research.

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

John F. Valliere-Douglass, T. Lewis, Sa A. Wang, 2017, Molecular Cancer Therapeutics.

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

P. Carter, D. Benjamin, S. Alley, 2018, Protein engineering, design & selection : PEDS.

Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.

D. Benjamin, K. Gordon, H. V. Van Epps, 2017, Blood.

Abstract B133: SEA technology: A novel strategy for enhancing antibody effector function

Peter D. Senter, Patrick J. Burke, P. Burke, 2009 .

Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody–Drug Conjugate Via Fc–FcγR Interaction

D. Benjamin, J. Hunter, Fu Li, 2019, Molecular Cancer Therapeutics.

Cancer Therapy : Preclinical Clinical Cancer Research Intracellular Activation of SGN-35 , a Potent Anti-CD 30 Antibody-Drug Conjugate

D. Benjamin, P. Senter, S. Alley, 2010 .

The Fucosylation Inhibitor, 2-Fluorofucose, Inhibits Vaso-Occlusion, Leukocyte-Endothelium Interactions and NF-ĸB Activation in Transgenic Sickle Mice

G. Vercellotti, P. Senter, N. Okeley, 2015, PloS one.

Abstract 3962: SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer.

A. Nesterova, Leia M. Smith, D. Sussman, 2013 .